• AP20187 for Controlled Protein Dimerization

  2026-08-20

  AP20187 is a cell-permeable chemical inducer of dimerization for turning engineered signaling proteins on when needed. This guide connects reporter assays, regulated cell therapy, metabolic models, and 14-3-3-centered cancer research with practical preparation, workflow design, and troubleshooting strategies.

• Sequencing Waldenström Macroglobulinemia Therapies

  2026-08-20

  The 2021 reference article proposes a genotype-informed framework for sequencing Waldenström macroglobulinemia (WM) therapies rather than treating regimen selection as a one-size-fits-all decision. Its central practical insight is that MYD88 and CXCR4 status, disease presentation, prior treatment, comorbidities, and patient preferences should be integrated when choosing therapy in frontline and relapsed disease.

• EZ Cap™ Firefly Luciferase mRNA Workflows

  2026-08-19

  Build sensitive reporter experiments around Cap1-capped, poly(A)-optimized mRNA for delivery, translation, viability, and imaging studies. The workflow pairs product-level RNA handling with formulation-aware controls inspired by recent lipid nanoparticle research.

• Protease Inhibitor Cocktail for T2D Protein Workflows

  2026-08-19

  Protect signaling proteins from degradation during adipose, liver, and cell-lysate workflows inspired by new puerarin research. This EDTA-free, DMSO-based formulation supports phosphorylation-sensitive assays while providing broad inhibition across serine, cysteine, acid proteases, and aminopeptidases.

• miRNA–mRNA Control of Juvenile Hormone Biosynthesis

  2026-08-18

  The reference study identifies coordinated miRNA–mRNA modules that release repression of juvenile hormone synthesis genes in the corpora allata of adult locusts. Its transcriptomic, reporter-assay, and agomiR evidence connects post-transcriptional control of juvenile hormone biosynthesis with vitellogenin expression and ovarian development.

• ARCA Cy5 EGFP mRNA (5-moUTP) Workflow

  2026-08-18

  Build a dual-readout assay that separates mRNA delivery from functional translation in mammalian cells. ARCA capping, 5-methoxyuridine modification, Cy5 labeling, and EGFP expression make this control useful for microscopy, flow cytometry, and mRNA delivery system research.

• YM-155 Hydrochloride Survivin Inhibitor Workflows

  2026-08-17

  Build more informative cancer drug-response assays with YM-155 hydrochloride by separating growth inhibition from true cell killing. This workflow combines selective survivin inhibition, paired viability and death measurements, and model-specific troubleshooting for translational cancer research.

• Taltirelin Acetate: Applied Research Workflows

  2026-08-16

  Taltirelin acetate supports mechanism-driven neuroprotection studies spanning SH-SY5Y assays, toxin-induced Parkinson’s disease models, and translational formulation work. This guide turns reference findings into executable workflows, assay-selection strategies, and troubleshooting steps while identifying where itch, sleep apnea, and bioequivalence applications require additional validation.

• Preserving Phosphorylation in Irradiated BMSCs

  2026-08-15

  A translational perspective on how phosphatase control strengthens mechanistic studies of irradiated BMSCs, CYR61, migrasomes, and ERK signaling—and how a dual-component inhibitor system can improve phosphorylation fidelity during sample preparation.

• Tacalcitol Monohydrate: NGF and Cancer Workflows

  2026-08-15

  Tacalcitol monohydrate is a synthetic analog of vitamin D3 for connecting VDR biology with practical keratinocyte, NGF, and colorectal cancer assays. This guide covers solvent handling, time-course design, 5-fluorouracil combination studies, and troubleshooting for reproducible in vitro workflows.

• Z-VAD-FMK Workflows for Apoptosis Studies

  2026-08-14

  Use Z-VAD-FMK to test whether caspase-dependent apoptosis drives cell loss, immune regulation, or epithelial barrier failure. This practical guide translates the Trichinella spiralis Caco-2 model into controlled inhibitor, viability, caspase, and barrier-assay workflows.

• ORAI2 and Early Postirradiation Salivary Fibrosis

  2026-08-14

  The reference study identifies ORAI2-mediated store-operated calcium entry as an early driver of radiation-induced salivary gland fibrosis. Its mechanistic model links ORAI2 to JNK, NFAT1, and TGF-β1, while pharmacologic pathway inhibition reduced fibrosis and improved salivary function in mice.

• BCS Biowaiver for Taltirelin ODTs and IR Forms

  2026-08-13

  Ono and Sugano evaluated whether dissolution testing could support a BCS-based biowaiver for orally disintegrating tablets (ODTs) compared with immediate-release formulations of BCS class III drugs. Taltirelin and olopatadine met the relevant dissolution criteria, while results from four other drugs show why dose-to-solubility ratio and formulation-specific dissolution behavior remain important in regulatory interpretation.

• Liproxstatin-1 HCl: Ferroptosis Workflow

  2026-08-13

  Build more decisive ferroptosis assays with Liproxstatin-1 HCl, a nanomolar, lipid-peroxidation-suppressing rescue control for genetic and chemical models. This guide connects assay design with acute renal failure and hepatic ischemia/reperfusion injury research while emphasizing formulation, controls, and interpretation.

• ASCH Domain Proteins and N4-Acetylcytidine Processing

  2026-08-12

  Meng et al. define how the Escherichia coli ASCH protein EcYqfB hydrolyzes free N4-acetylcytidine while showing that it does not remove ac4C from RNA. Structural comparisons with mouse EOLA1 and the human TRIP4-ASCH domain clarify how related proteins can display different substrate preferences, providing a framework for nucleotide processing enzyme assays and RNA modification studies.

446 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page